Jacobson Pharma Corporation

Jacobson Pharma Corporation EBIT

The EBIT of Jacobson Pharma Corporation (2633.HK) as of Nov 5, 2026 is 353.18 M HKD. In the previous year, EBIT was 414.60 M HKD — a change of -14.81% (lower).

EBIT

353.18 MHKD

YoY

-14.81%

Last updated:

In 2026, Jacobson Pharma Corporation's EBIT was 353.18 M HKD, a -14.81% increase from the 414.60 M HKD EBIT recorded in the previous year.

The Jacobson Pharma Corporation EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2029 (e)
519.12 M HKD
Jan 1, 2030 (e)
252.42 M HKD
Jan 1, 2031 (e)
286.36 M HKD
Jan 1, 2032 (e)
318.82 M HKD
Jan 1, 2033 (e)
382.11 M HKD
Jan 1, 2034 (e)
432.98 M HKD
Jan 1, 2035 (e)
466.89 M HKD
Jan 1, 2036 (e)
600.12 M HKD
The Jacobson Pharma Corporation EBIT history
YEAREBITYoY
est600.12 MHKD+28.53%
est466.89 MHKD+7.83%
est432.98 MHKD+13.31%
est382.11 MHKD+19.85%
est318.82 MHKD+11.34%
est286.36 MHKD+13.45%
est252.42 MHKD-51.38%
est519.12 MHKD+11.19%
est466.89 MHKD+9.30%
est427.17 MHKD+20.95%
353.18 MHKD-14.81%
414.60 MHKD+24.46%
333.13 MHKD+4.39%
319.10 MHKD+43.17%
222.89 MHKD+20.15%
185.50 MHKD-37.21%
295.44 MHKD-12.87%
339.07 MHKD+21.05%
280.11 MHKD+10.20%
254.19 MHKD+29.72%
195.96 MHKD+41.14%
138.84 MHKD-37.72%
222.92 MHKD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jacobson Pharma Corporation Revenue

Jacobson Pharma Corporation Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2029 (e)
2.00 B HKD
519.12 M HKD
454.05 M HKD
Jan 1, 2030 (e)
1.71 B HKD
252.42 M HKD
166.93 M HKD
Jan 1, 2031 (e)
1.84 B HKD
286.36 M HKD
194.96 M HKD
Jan 1, 2032 (e)
1.97 B HKD
318.82 M HKD
221.76 M HKD
Jan 1, 2033 (e)
1.55 B HKD
382.11 M HKD
274.03 M HKD
Jan 1, 2034 (e)
1.63 B HKD
432.98 M HKD
316.03 M HKD
Jan 1, 2035 (e)
1.73 B HKD
466.89 M HKD
344.04 M HKD
Jan 1, 2036 (e)
2.00 B HKD
600.12 M HKD
454.05 M HKD

Jacobson Pharma Corporation Margins

Jacobson Pharma Corporation stock margins

The Jacobson Pharma Corporation margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Jacobson Pharma Corporation. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Jacobson Pharma Corporation.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2029 (e)
43.19 %
25.91 %
22.67 %
Jan 1, 2030 (e)
43.19 %
14.79 %
9.78 %
Jan 1, 2031 (e)
43.19 %
15.57 %
10.60 %
Jan 1, 2032 (e)
43.19 %
16.21 %
11.27 %
Jan 1, 2033 (e)
43.19 %
24.73 %
17.73 %
Jan 1, 2034 (e)
43.19 %
26.53 %
19.36 %
Jan 1, 2035 (e)
43.19 %
26.99 %
19.88 %
Jan 1, 2036 (e)
43.19 %
29.96 %
22.67 %

Jacobson Pharma Corporation Stock analysis

What does Jacobson Pharma Corporation do? Jacobson Pharma Corp. Ltd. generates revenue through its Generic Drugs segment, which develops, manufactures, and distributes off-patent medicines for public and private sectors. The Branded Healthcare segment offers branded medicines, proprietary Chinese medicines, and health and wellness products. Both segments operate primarily in Hong Kong, serving healthcare providers and consumers seeking cost-effective pharmaceutical solutions. The company employs 1,789 full-time employees to support its operations across these segments. The Generic Drugs segment focuses on off-patent medicines for various therapeutic uses, targeting hospitals, clinics, and pharmacies in both public and private healthcare systems. The Branded Healthcare segment caters to consumers and healthcare providers through branded pharmaceuticals and wellness products, emphasizing proprietary Chinese medicines as a key offering. Revenue streams are derived from direct sales of these products within Hong Kong's healthcare market. Jacobson Pharma's business model relies on the dual revenue streams from generic and branded pharmaceuticals. The company's product portfolio includes off-patent medicines under the Generic Drugs segment and branded medicines under the Branded Healthcare segment, both contributing to its overall sales. The firm's operations are structured around these two segments, with all activities concentrated in Hong Kong. Jacobson Pharma Corporation is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Jacobson Pharma Corporation's EBIT

Jacobson Pharma Corporation's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Jacobson Pharma Corporation's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Jacobson Pharma Corporation's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Jacobson Pharma Corporation’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Jacobson Pharma Corporation stock

EBIT of Jacobson Pharma Corporation is 353.18 M HKD in 2026.

EBIT of Jacobson Pharma Corporation changed from 414.60 M HKD to 353.18 M HKD, representing a -14.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Jacobson Pharma Corporation since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's HKD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Jacobson Pharma Corporation historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Jacobson Pharma Corporation

All Key Metrics — Jacobson Pharma Corporation